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PURPOSE: Vitreous hemorrhage (VH) is a rare but serious complication of the 
eyes with exudative age-related macular degeneration (AMD). This retrospective 
study was designed to evaluate various clinical factors that may affect the visual 
prognosis of patients with VH secondary to exudative AMD. 
DESIGN: Retrospective case study. 
METHODS: We intensively documented 31 cases of VH secondary to exudative 
AMD and retrospectively analyzed best-corrected visual acuity (BCVA). All eyes 
underwent standard pars plana vitrectomy (PPV) for treating VH. Three subgroups 
were created according to the clinical course and treatment history before the 
occurrence of VH: (1) Gas group (7 eyes), Pneumatic displacement with SF6 gas 
performed to treat massive submacular hemorrhage; (2) PDT group (9 eyes), 
Photodynamic therapy performed to treat exudative AMD; (3) Untreated group (15 
eyes), No treatment performed. 
RESULTS: As a whole, BCVA before the occurrence of VH was 1.05±0.59 
(LogMAR). After the occurrence of VH, BCVA before PPV dropped to 2.61±0.82. 
After the operation, final BCVA significantly improved to 1.25±0.73 (P<10-8). In a 
subgroup analysis, no statistically significant difference was seen among the three
subgroups at any time point. We found that the eyes whose fellow eye had 
exudative AMD showed significantly poor final BCVA compared to the unilateral 
cases (0.92±0.57 and 1.49±0.72, P=0.02). 
CONCLUSIONS: PPV can improve visual acuity in the eyes with VH secondary to 
AMD, although effectiveness is limited. Medical practitioners should be cautious of 
the visual prognosis, especially in the cases whose fellow eye has exudative AMD. 
(Total: 244 words)
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Choroidal neovascularization (CNV) secondary to exudative age-related macular 
degeneration (AMD) has a poor visual prognosis due to fundus manifestations that 
include pigment epithelial detachment, retinal detachment, sub-retinal/macular 
hemorrhage, hard exudates, macular edema, and subretinal fibrosis. Vitreous 
hemorrhage (VH) is a rare but serious complication of exudative AMD.1-3 VH itself 
contributes to vision loss in AMD and is considered a sign of AMD progression. 
Although unstable neovasculature may be related to VH, the precise mechanisms that 
lead to ocular VH with exudative AMD remain unclear. In some cases, VHs may be 
spontaneously absorbed over time; however, pars plana vitrectomy (PPV) is often 
required to remove the hemorrhage. PPV surgery provides a relatively good visual 
prognosis.4, 5  
 In ocular VH with exudative AMD, submacular hemorrhage often precedes the 
occurrence of spontaneous VH.2 VH can occur in cases of massive submacular 
hemorrhage following treatments such as pneumatic displacement.6, 7 Photodynamic 
therapy (PDT) for the treatment of exudative AMD can also cause VH.8, 9 However, 
there is little information about how the clinical course of the disease affects visual 
prognosis in eyes with VH due to exudative AMD. 
 To clarify the factors that affect the prognosis of VH secondary to exudative 
AMD, we documented the clinical courses of patients with exudative AMD that 
underwent PPV to remove VH. Clinical factors likely to influence visual prognosis were 
investigated. We additionally evaluated the efficacy of pars plana vitrectomy (PPV) for 





































































For this interventional case study, we retrospectively reviewed the medical 
records of 979 consecutive patients with exudative AMD who were treated at the 
Macula Service, Department of Ophthalmology, Kyoto University Hospital, from January 
2004 to September 2008. Inclusion criteria were as follows: (1) the occurrence of VH 
during the follow-up period in the clinic, (2) a diagnosis of exudative AMD during follow-
up, (3) treatment with PPV for VH, and (4) a postoperative follow-up period greater than 
three months. Patients were divided into 3 subgroups depending on their clinical course 
before the occurrence of VH: (1) gas group: pneumatic displacement with SF6 gas was 
used to treat massive submacular hemorrhage before the occurrence of VH; (2) PDT 
group: PDT was used to treat exudative AMD before the occurrence of VH; and (3) 
untreated group: no treatment was performed before the occurrence of VH. For the 
purposes of this study, patients with polypoidal choroidal vasculopathy (PCV) and 
retinal angiomatous proliferation (RAP) were considered to have exudative AMD and 
were included in the study. We use the term AMD to mean exudative AMD that could 
not be diagnosed as PCV or RAP. Patients with other types of CNV, i.e. pathologic 
myopia, angioid streaks, RAP, idiopathic CNV, presumed ocular histoplasmosis 
syndrome, and other secondary CNV were excluded from this study. Patients with other 
retinal/macular abnormalities, i.e., retinal macroaneurysm, diabetic retinopathy, retinal 
vein occlusion, or uveitis, were also excluded from the study.  
A PCV diagnosis was based on an indocyanine green (ICG) angiogram that 
showed polypoidal structures along the border of the branching vascular network. A 
polypoidal lesion can appear as a single polyp or as a cluster of polyps. In most PCV 
cases, reddish-orange subretinal nodules were seen under ophthalmoscopic 
examination that corresponded to the polypoidal lesions seen by ICG angiography.  
All patients had comprehensive ophthalmologic examinations, including best-corrected 
visual acuity (BCVA) measurements, binocular ophthalmoscopy, slit-lamp 
biomicroscopy with a contact lens, color fundus photography, fluorescein angiography, 
ICG angiography, and optical coherence tomography (OCT). Fluorescein angiography 
and ICG angiography were performed simultaneously using a confocal laser scanning 
system (HRA-2; Heidelberg Engineering, Dossenheim, Germany). Four types of OCT 
instruments were used (Stratus OCT, Carl Zeiss, Dublin, CA; OCT-ophthalmoscope, 
Nidek, Gamagori, Japan; 3D OCT-1000, Topcon, Tokyo, Japan; RTVue, Optovue 




































































every 3 months. In addition, patients were advised to visit the clinic if they felt their 
vision was worsening. 
 To treat VH, standard three-port PPV was performed on all patients in the study 
using a 20-gauge or 23-gauge system. Six experienced surgeons in our macular clinic 
performed all surgeries. Phacoemulsification and intraocular lens implantation was 
combined in all phakic eyes because of the expected progressive nuclear sclerosis. 
Fluid-air exchange and sulfur hexafluoride (SF6) gas tamponade was performed in 
some cases.  
To treat massive submacular hemorrhage, pneumatic displacement was 
performed using 0.5 ml of 100% SF6 gas injected into the vitreous cavity with a 30-
gauge needle. Patients were instructed to maintain a prone position at least 4 days. 
PDT with verteporfin to treat exudative AMD was performed according to standard 
procedures. A 689-nm laser system (Carl Zeiss, Dublin, CA) was used, and 50-J/mm2 
energy was delivered with an 83-second exposure time.   
For statistical analysis, counting fingers (CF), hand motion (HM) and light 
perception (LP) were considered to indicate decimal visual acuity of 0.005, 0.001 and 
0.0005, respectively. The BCVA was determined using the Landolt ring test and 
converted into the logarithm of the minimum angle of resolution (logMAR). All values are 
reported as the mean ± standard deviation. Continuous variables between two groups 
were compared using the Student’s t-test (two-tailed). Continuous variables between 
three groups were compared by one-way analysis of variance. Multivariate linear 
regression analysis was performed to correlate final visual acuity with other clinical 
parameters. All analyses were performed using a commercial software program (SPSS 
v.13.0; SPSS, Chicago, IL). A difference was considered statistically significant when 





































































This study included 31 patients, each with one eye with VH due to exudative 
AMD (3.2% of the 979 age-related exudative AMD patients) (Table 1). The patients 
ranged in age from 55 to 86 years (mean ± standard deviation, 73.8 ± 7.7 years). The 
mean postoperative follow-up period was 19.9 ± 14.2 months (range, 5–52 months). Of 
the 31 eyes, 22 (71%) were diagnosed as PCV by angiographic analysis; the other 9 
were diagnosed as AMD. Patient characteristics are summarized in Table 1. 
Submacular hemorrhage and hemorrhagic pigment epithelial detachment was detected 
prior to VH in 14 and 15 eyes, respectively. Seven patients presented with VH at their 
initial visit to the clinic. The CNV lesion was located parafoveally in patients 2, 12, 13, 
14, 15, 17, 18, and 21 (n = 8) (Table 1). 
Vitreous hemorrhage was observed after pneumatic displacement of submacular 
hemorrhage using intravitreal injection of SF6 gas in 7 eyes (the gas group); the mean 
period from gas injection to the occurrence of VH was 51 ± 102 days (range, 3–300 
days). Before VH, PDT was performed in 9 eyes (the PDT group). In the PDT group, the 
mean period from the last PDT to the occurrence of VH was 14 ± 12 months (range, 
0.5–31 months). In the other 15 eyes (the untreated group), no treatment was 
performed before VH was detected. PPV was performed in all cases to remove the VH 
and was performed in conjunction with phacoemulsification in 25 eyes (81%).  
The mean BCVA (at the last documentation for each eye) before VH in the 25 
patients who were seen in the clinic before the VH occurred was 1.05 ± 0.59 LogMAR 
units. After the occurrence of VH, the mean BCVA decreased to 2.61 ± 0.82 and then 
showed significant improvement 3 months after PPV surgery (P < 10-8); improvements 
in BCVA were maintained during the follow-up period (Figure 1, top). The mean BCVA 6 
months after surgery was 1.23 ± 0.78 and was 1.12 ± 0.82 12 months after surgery (P < 
10-8). Although the improvement in BCVA after surgery was more than 0.3 LogMAR 
units in 26 eyes (84%), the final BCVA was not satisfactory in most cases. Only 8 eyes 
(26%) had a final BCVA ≥ 1.0 LogMAR units. When analyzing the five cases with 
relatively good visual prognosis (less than LogMAR 0.6, cases 4, 7, 12, 18，and 21), 
we found that all cases were PCV and that four patients (80%) were unilaterally 
affected. In addition, all five cases had polypoidal lesions, pigment epithelial 
detachment, or submacular hemorrhage that was para- or extrafoveal. Three of the 5 
eyes (60%) showed branching vascular networks under the fovea (cases 7, 18, and 21).   
In the subgroup analysis, BCVA before the occurrence of VH was 0.82 ± 0.30 in 




































































 After the occurrence of VH, BCVA before PPV was 2.46 ± 0.87 in the gas group, 
2.54 ± 0.92 in the PDT group, and 2.71 ± 0.79 in the untreated group. The final BCVA 
was 0.90 ± 0.56 in the gas group, 1.35 ± 0.72 in the PDT group, and 1.34 ± 0.79 in the 
untreated group. There seemed to be a trend for the gas group to have a better visual 
prognosis compared to other groups; however, no statistically significant difference was 
seen in the three subgroups at any time point (Figure 1, middle). In our series, 7 of the 9 
PDT cases that developed VH had only one PDT session. In the other 2 cases (cases 9 
and 16), the patient received multiple PDT sessions before VH. In most of the PDT 
cases, the lesion was stabilized after PDT, and VH occurred with the recurrence of 
AMD. In 2 cases (cases 9 and 11 in Table 1), PDT did not stabilize the lesion; 
subsequently, VH occurred. 
Interestingly, the percentage of bilaterally affected exudative AMD patients was 
high for the VH cases (16 eyes, 52%) compared to all the exudative AMD cases in our 
clinic (21%). Therefore, we compared unilaterally (n = 15) and bilaterally (n = 16) 
affected patients. BCVA before the occurrence of VH was 1.01 ± 0.72 in the unilateral 
group and 1.07 ± 0.48 in the bilateral group, while BCVA before PPV was 2.69 ± 0.62 
and 2.55 ± 0.96, respectively. There were significant differences in BCVA between the 
two groups at 3 months (0.95 ± 0.54 vs 1.56 ± 0.82; P = 0.02), 6 months (0.87 ± 0.56 vs 
1.55 ± 0.83; P = 0.01), 12 months (0.71 ± 0.58 vs 1.53 ± 0.84; P = 0.02), and at the final 
end point (P = 0.02) (Figure 1, bottom).  
Using multivariate regression analysis, we also examined other factors that might 
have influenced the 6-month BCVA (Table 2). Explanatory variables were age, sex, 
hypertension, diabetes mellitus, anticoagulant medication, history of smoking, 
angiographic subtype, submacular hemorrhage before VH, phacoemulsification and 
intraocular lens implantation combined vitrectomy, logMAR before VH, logMAR before 
PPV, and logMAR of the fellow eye. None of these factors showed statistical 
significance.  
Avastin injection was used in cases 1, 6, 28, and 30. In all of these cases, the 





































































 In our series of 31 eyes with VH secondary to CNV, PCV occurred in a high 
percentage of cases (71%). PCV is a subtype of exudative AMD, and the first published 
case of PCV was reported as posterior uveal bleeding syndrome.10 Subsequent to that 
report, there have been numerous studies of PCV. As detected by ICG angiography, 
polypoidal vasculature rather than massive bleeding is now considered a common and 
distinctive angiographic feature of the disease. Bleeding is still an important 
characteristic of PCV, and the rate of hemorrhagic complications, including hemorrhagic 
pigment epithelial detachment in PCV, is higher than in other types of AMD.11, 12  
 VH is a hemorrhagic complication of exudative AMD that can cause severe vision 
loss. Although the incidence of VH in exudative AMD is not high (3.2% of 979 cases in 
our case series), the incidence of PCV among the VH cases was higher (71%) than the 
incidence of PCV among all exudative AMD cases (47% in our clinic). PCV should thus 
be considered when patients with exudative AMD present with VH.  
Anticoagulant medications can contribute to the incidence of hemorrhagic 
complications in exudative AMD, for example in submacular hemorrhage or VH.1, 13 In 
the current study, only 16% of the 31 patients were on anticoagulants, and in our 
previous report on hemorrhagic complications in PCV cases after PDT, anticoagulants 
did not affect the incidence of complications.9 Larger case series are needed to fully 
explore this issue. During the observation period in this study, medications were not 
related to changes in BCVA. 
 In this study, the clinical courses leading to VH did not affect the significant 
differences we observed in BCVA (3-month mean BCVA: gas group 0.94 ± 0.59, PDT 
group 1.36 ± 0.65, untreated group 1.36 ± 0.86; 6-month mean BCVA: gas group 0.79 ± 
0.55, PDT group 1.35 ± 0.78, untreated group 1.38 ± 0.85; 12-month mean BCVA: gas 
group 0.70 ± 0.57, PDT group 1.28 ± 0.90, untreated group 1.19 ± 0.86). Although the 
difference was not statistically significant (P=), eyes affected by VH in the six months 
after PDT tended to have a lower final BCVA than other eyes in the PDT group. There is 
no evidence that PDT itself triggers VH, but we previously found that 6.6% of PVC 
resulted in VH following PDT.9 It is possible that VH after PDT may result from 
incomplete tissue and vascular repair, indicating a poor prognosis. Further studies are 
required to clarify this issue; in the meantime, clinicians should focus on cases in which 
VH occurs immediately after PDT.  
 In our series of 979 patients, there were 15 patients who were treated with 




































































were included in this study. The final mean visual acuity for these 7 cases was 0.90 ± 
0.56 logMAR, whereas that of the other 8 cases who did not develop VH was 0.88 ± 
0.6. Because there was no significant difference between the two groups, it seems that 
development of VH after gas injection may have little effect on the prognosis of 
submacular hemorrhage. As shown in Figure 1, there was a tendency for the gas group 
to have better visual acuity compared to the untreated group. Gas injection should be 
considered for submacular hemorrhage, even if the treatment is a risk factor for VH. We 
calculated the risks associated with several factors that might affect the incidence of VH 
after pneumatic displacement. However, intra-ocular lens implantation, hypertension 
(HT), diabetes mellitus (DM), history of smoking, PDT, and anticoagulant medication 
were not correlated with the incidence of VH. 
 We found that cases that were bilaterally affected by exudative AMD had very 
poor visual prognosis after VH compared to unilateral cases. We previously reported a 
bilaterally affected case with a different a biological response to PDT treatment that had 
a worse visual prognosis compared to a unilaterally affected case.14 In addition, there is 
a loss of control of pathological vessels and tissues by circulating hematopoietic 
stem/progenitor cells in bilaterally affected cases.15 We noted a high percentage of 
bilaterally affected cases (52%) in our VH case series (this study). In general, the 
incidence of bilateral exudative AMD in Japanese patients is ~10-20%.16, 17 This 
extremely high rate of bilateral exudative AMD in VH cases suggests a relationship 
between susceptibility to VH and bilateral affection. In genomic studies, patients with 
high-risk homozygous ARMS2 polymorphisms tend to have bilateral AMD,18, 19 and this 
high-risk homozygous polymorphism is frequently seen in patients with VH.20 These 
data suggest a common genetic background that that increases susceptibility to VH and 
bilateral exudative AMD. These reports, along with the data in the current study, raise 
the possibility that different biological responses or pathological causes may underlie 
the differences between bilateral and unilateral exudative AMD cases. Further 
investigations should clarify the relationship between susceptibility to VH and bilateral 
exudative AMD.  
In conclusion, the current study searched for prognostic factors of VH secondary 
to exudative AMD. We found that (1) there is a high susceptibility to PCV in cases with 
VH secondary to exudative AMD, (2) PPV can restore visual acuity to a pre-VH level, 
although relatively good visual prognosis can only be obtained in limited cases, and (3) 
visual prognosis in bilaterally affected patients is poor. Although we included more 




































































is necessary for clarify the prognosis of VH in exudative AMD cases. Further efforts 
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Figure 1. Changes in visual acuity before and after pars plana vitrectomy (PPV) for 
vitreous hemorrhage (VH) secondary to age-related macular degeneration (AMD). (Top) 
LogMAR units before VH (pre-VH), after VH (pre-PPV), and final visual acuity after PPV 
(final). *: P < 10-6, compared to pre-PPV. (Middle) Comparison of LogMAR changes 
among the three subgroups. Gas = patients treated by intravitreal injection of SF6 gas 
for displacing submacular hemorrhage before the occurrence of VH. PDT = patients 
treated by photodynamic therapy for exudative AMD before the occurrence of VH. 
Untreated = patients without any treatment before the occurrence of VH. (Bottom) 
Comparison of LogMAR changes between patients with unilateral and bilateral 
exudative AMD. *: P < 0.05.  
 
Figure 2. A case of vitreous hemorrhage (VH) secondary to exudative age-related 
macular degeneration resulting in relatively good visual prognosis (case 7). (Top left) 
The right eye is normal, with decimal visual acuity of 1.2. (Top right) The left eye 
showed massive submacular hemorrhage and hemorrhagic pigment epithelial 
detachment (PED) before the occurrence of VH. (Bottom left) Indocyanine green 
angiogram showed a branching vascular network and polypoidal structure at the border 
of the network. Fluorescence is blocked at the PED lesions. (Bottom right) Pars plana 
vitrectomy (PPV) was performed after VH developed. Macular hemorrhage was 
absorbed and the decimal visual acuity of the left eye improved to 1.0 nine months after 
PPV.  
 
Figure 3. A case of vitreous hemorrhage (VH) secondary to exudative age-related 
macular degeneration (AMD) resulting in poor visual prognosis (case 15). (Top left) A 
fundus photograph of the right eye before the occurrence of VH. Large hemorrhagic 
pigment epithelial detachment (PED) can be seen beyond the vascular arcade. Orange 
subretinal lesions were observed at the border of the PED. The decimal visual acuity 
was 0.2. (Top right) The left eye showed fibrovascular scar formation secondary to old 
exudative AMD. (Bottom left) Indocyanine green angiogram of the right eye showed a 
large vascular network at the macula and aneurismal structures at the border of the 
network. (Bottom right) After the occurrence of VH, the patient underwent PPV. A huge 
choroidal neovascular membrane was seen at the macula. Ten months after PPV, the 
decimal visual acuity was 0.02.  
 
































1 71 M No No Yes No Unilateral PCV Yes Gas (7) PPV+PEA+IOL 0.3 N/A 0.1 29 
2 71 M No No No Yes Bilateral PCV Yes Gas (10) PPV+PEA+IOL 0.2 0.1 0.1 6 
3 78 M No No No Yes Unilateral PCV Yes Gas (19) PPV+PEA+IOL 0.1 HM 0.04 5 
4 70 M No No No Yes Bilateral AMD Yes Gas (7) PPV+PEA+IOL 0.08 CF 0.3 24 
5 68 M No No No No Unilateral AMD Yes Gas (300) PPV+PEA+IOL 0.06 HM 0.02 52 
6 68 M Yes Yes Yes No Bilateral AMD Yes Gas (10) PPV+PEA+IOL 0.15 HM 0.2 48 
7 71 M Yes No No No Unilateral PCV Yes Gas (6) PPV+PEA+IOL 0.4 N/A 1.0  13 
8 81 M Yes No No No Bilateral AMD No PDT (360) PPV 0.04 CF 0.07 15 
9 73 M Yes No No Yes Bilateral PCV No PDT (45) PPV+PEA+IOL 0.1 LP HM 13 
10 78 M Yes No No Yes Bilateral PCV No PDT (180) PPV 0.15 0.07 0.06 37 
11 81 M No No No Yes Bilateral PCV Yes PDT (15) PPV 0.07 0.07 0.05 8 
12 70 M No No No No Unilateral PCV No PDT (930) PPV+PEA+IOL 0.3 0.01 0.5 12 
13 76 M No No No Yes Unilateral PCV No PDT (810) PPV+PEA+IOL 0.1 HM 0.07 11 
14 85 M Yes No Yes No Bilateral PCV No PDT (870) PPV+PEA+IOL 0.07 LP 0.08 8 
15 68 M No No No Yes Bilateral PCV No PDT (420) PPV+PEA+IOL 0.2 LP 0.02 10 
16 55 F No No No No Unilateral PCV No PDT (60) PPV+PEA+IOL 0.1 LP 0.06 23 
17 80 M Yes No No Yes Unilateral PCV Unknown Untreated PPV+PEA+IOL N/A HM 0.2 25 
18 77 F Yes No No No Unilateral PCV Yes Untreated PPV+PEA+IOL 0.3 HM 1.0  29 
19 58 M Yes No No Yes Unilateral PCV Yes Untreated PPV+PEA+IOL 0.06 HM 0.02 20 
20 78 M No No No Yes Bilateral PCV Yes Untreated PPV+PEA+IOL 0.04 LP 0.03 11 
21 65 M Yes No No Yes Unilateral PCV Unknown Untreated PPV+PEA+IOL N/A CF 0.4 12 
22 58 M No No No Yes Unilateral PCV Unknown Untreated PPV+PEA+IOL N/A 0.09 0.2 8 
23 80 M Yes Yes Yes No Bilateral PCV Unknown Untreated PPV N/A LP HM 6 
24 75 F Yes No No No Unilateral PCV Unknown Untreated PPV+PEA+IOL N/A CF 0.08 8 
Table1
25 82 M No No Yes Yes Bilateral PCV No Untreated PPV 0.02 LP CF 17 
26 74 M Yes No No Yes Bilateral AMD Yes Untreated PPV+PEA+IOL 0.08 HM 0.09 52 
27 73 F No No No Yes Unilateral AMD Yes Untreated PPV 0.2 HM 0.1 7 
28 77 M Yes No No Yes Bilateral AMD Yes Untreated PPV+PEA+IOL 0.01 LP 0.01 34 
29 86 F Yes No No Yes Unilateral AMD Unknown Untreated PPV+PEA+IOL HM HM 0.02 8 
30 79 M Yes Yes No No Bilateral PCV Unknown Untreated PPV+PEA+IOL N/A 0.15 0.1 43 
31 81 M No No No No Bilateral AMD No Untreated PPV+PEA+IOL 1.0  HM 0.01 22 
CNV=choroidal neovascularization; HT=hypertension; DM=diabetes mellitus: AMD = age-related macular degeneration; CF = counting finger; Gas = Intravitreal injection of SF6 gas; HM = 
hand motion; IOL = intraocular lens implantation; LP = light perception; m = months; PCV = polypoidal choroidal vasculopathy; PDT = photodynamic therapy; PEA = phacoemulsification 
and aspiration; PPV = pars plana vitrectomy; VH = vitreous hemorrhage; VA=visual acuity; y = years. The numbers in the “Treatment before VH” column indicated the months between the 
treatment and VH 
 
 
TABLE 2. Multivariate analysis of the factors which might have influenced the BCVA  
 
Independent Variable β coefficient P value 
Age -0.20  0.47  
Sex -0.45  0.11  
Hypertension 0.04  0.90  
Diabetes mellitus -0.29  0.34  
Medication of anticoagulant 0.19  0.53  
History of smoking 0.25  0.42  
Angiographic subtype of PCV -0.01  0.98  
Submacular hemorrhage before VH -0.11  0.72  
PEA+IOL combined -0.20  0.52  
LogMAR of pre VH -0.06  0.86  
LogMAR of pre PPV 0.43  0.14  
LogMAR of fellow eye -0.07  0.81  
IOL = intraocular lens implantation; PCV = polypoidal choroidal 
vasculopathy; PEA = phacoemulsification and aspiration; PPV = pars 





Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
